Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

259 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Humoral and cellular correlates of a novel immune-related adverse event and its treatment.
Gonugunta AS, von Itzstein MS, Mu-Mosley H, Fattah F, Farrar JD, Mobely A, Rashdan S, Lai S, Bhai SF, Bermas BL, Karp D, Li QZ, Wakeland EK, Gerber DE. Gonugunta AS, et al. Among authors: gerber de. J Immunother Cancer. 2021 Dec;9(12):e003585. doi: 10.1136/jitc-2021-003585. J Immunother Cancer. 2021. PMID: 34880115 Free PMC article.
Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer.
Gerber DE, Boothman DA, Fattah FJ, Dong Y, Zhu H, Skelton RA, Priddy LL, Vo P, Dowell JE, Sarode V, Leff R, Meek C, Xie Y, Schiller JH. Gerber DE, et al. Lung Cancer. 2015 Dec;90(3):534-41. doi: 10.1016/j.lungcan.2015.10.008. Epub 2015 Oct 9. Lung Cancer. 2015. PMID: 26474959 Free PMC article. Clinical Trial.
Chemotherapy for Advanced Non-small Cell Lung Cancer.
Dietrich MF, Gerber DE. Dietrich MF, et al. Among authors: gerber de. Cancer Treat Res. 2016;170:119-49. doi: 10.1007/978-3-319-40389-2_6. Cancer Treat Res. 2016. PMID: 27535392 Review.
Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505).
Gerber DE, Urbanic JJ, Langer C, Hu C, Chang IF, Lu B, Movsas B, Jeraj R, Curran WJ, Bradley JD. Gerber DE, et al. Clin Lung Cancer. 2017 May;18(3):333-339. doi: 10.1016/j.cllc.2016.10.009. Epub 2016 Oct 26. Clin Lung Cancer. 2017. PMID: 27923550 Free PMC article. Clinical Trial.
Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.
Huang X, Motea EA, Moore ZR, Yao J, Dong Y, Chakrabarti G, Kilgore JA, Silvers MA, Patidar PL, Cholka A, Fattah F, Cha Y, Anderson GG, Kusko R, Peyton M, Yan J, Xie XJ, Sarode V, Williams NS, Minna JD, Beg M, Gerber DE, Bey EA, Boothman DA. Huang X, et al. Among authors: gerber de. Cancer Cell. 2016 Dec 12;30(6):940-952. doi: 10.1016/j.ccell.2016.11.006. Cancer Cell. 2016. PMID: 27960087 Free PMC article.
Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer.
Beg MS, Huang X, Silvers MA, Gerber DE, Bolluyt J, Sarode V, Fattah F, Deberardinis RJ, Merritt ME, Xie XJ, Leff R, Laheru D, Boothman DA. Beg MS, et al. Among authors: gerber de. J Surg Oncol. 2017 Jul;116(1):83-88. doi: 10.1002/jso.24624. Epub 2017 Mar 27. J Surg Oncol. 2017. PMID: 28346693 Free PMC article.
259 results